Julian Levell, Ph.D.
Dr Julian Levell is VP of drug discovery with responsibility for our small molecule research efforts in medicinal chemistry, molecular modelling, structural biology, protein production, DMPK, automation, compound management, biochemistry and biophysics. Julian carried out his PhD research at Cardiff University on organic photochromic molecules, and invented a series of compounds which were incorporated into Transitions™ lenses. He went on to do postdoctoral research at University of Florida with Prof Alan Katritzky on the development of novel heterocyclic chemistry methodology. Since then, Julian has worked in biotech and pharma research for over 20 years, spending time at Centaur Pharmaceuticals, Aventis (Sanofi), and the Novartis Institutes for Biomedical Research. He joined Constellation as Executive Director of chemistry in 2016. During his career, Julian has led teams and projects across multiple disease areas including cardiovascular, diabetes, asthma, neuroscience, and oncology; with 9 programs transitioning through IND. He has also spent time in South Africa to help build drug discovery capabilities at the H3D research center in Cape Town. Julian has over 40 patents and publications, and is a core member of the NIH National Cancer Institutes (NCI) Experimental Therapeutics (NExT) review committee and Special Emphasis Panel (SEP).